Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors
Authors:
- 7 January 2013
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Safety
- Vol. 12 (2) , 235-246
Abstract
(2013). Clinical safety of biosimilar recombinant human granulocyte colony-stimulating factors. Expert Opinion on Drug Safety: Vol. 12, No. 2, pp. 235-246. doi: 10.1517/14740338.2013.770472Keywords
This publication has 31 references indexed in Scilit:
- Biosimilars: what clinicians should knowBlood, 2012
- Clinical safety of biosimilar recombinant human erythropoietinsExpert Opinion on Drug Safety, 2012
- Impact of Primary Prophylaxis With Granulocyte Colony-Stimulating Factor on Febrile Neutropenia and Mortality in Adult Cancer Patients Receiving Chemotherapy: A Systematic ReviewJournal of Clinical Oncology, 2007
- How similar do 'biosimilars' need to be?Nature Biotechnology, 2004
- Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapyEuropean Journal of Cancer, 1993
- Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung CancerNew England Journal of Medicine, 1991
- Recombinant Human Granulocyte Colony-Stimulating Factor: Effects on Normal and Leukemic Myeloid CellsScience, 1986
- Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factorNature, 1986
- The Granulocyte-Macrophage Colony-Stimulating FactorsScience, 1985
- The nature and action of granulocyte-macrophage colony stimulating factorsBlood, 1980